Modeling Parkinson's disease using induced pluripotent stem cells

Current Neurology and Neuroscience Reports

Volumn 12, Issue 3, 2012, Pages 237-242

  Byers, Blake ^a,b,c   Lee, Hsiao Lu ^a,b   Pera, Renee Reijo ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c GOOGLE INC   (United States)

Author keywords

Synuclein; Development; Disease modeling; Induced pluripotent stem cells; Lewy bodies; Neurodegenerative disease; Parkinson's disease; Phenotype identification; Protein aggregation; Ubiquitin

Indexed keywords

ALPHA SYNUCLEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; HYDROGEN PEROXIDE; LEUCINE RICH REPEAT KINASE 2; OXIDOPAMINE;

ALPHA SYNUCLEIN GENE; ARTICLE; CELL DIFFERENTIATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; FAMILIAL DISEASE; GENE; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HOMOZYGOTE; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; LEWY BODY; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PLURIPOTENT STEM CELL; TRANSGENIC ANIMAL; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; DOPAMINERGIC NEURONS; HUMANS; MODELS, BIOLOGICAL; MUTATION; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84861231381     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0270-y     Document Type: Article

References (65)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4.
2. Wakabayashi K, Takahashi H.Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol. 1997;38 Suppl 2:2-7. (Pubitemid 27453771)
3. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59:591-6.
4. Lewy F. in Pathologische Anatomie. In: Handbuch der Neurologie. (ed M Lewandowsky) Ch. 920-933, 13 Springer-Verlag; 1912.
5. Lewy F. Zur pathologischen Anatomie der Paralysis Agitans. Deutsche Zeitschrift fur Nervenheilkunde. 1913;50:50-5.
6. Cookson MR. Alpha-Synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
7. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259.
8. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819-22. (Pubitemid 37339614)
9. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(Suppl):S10-7. (Pubitemid 38901862)
10. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature. 1963;197:192-3.
11. Duffy PE, Tennyson VM. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. J Neuropathol Exp Neurol. 1965;24:398.
12. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010;31:763-80.
13. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(R1):R48-59.
14. Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol. 2007;17:331-7. (Pubitemid 46880329)
15. Chartier-Harlin MC, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167-9.
16. Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276:2045-7. (Pubitemid 27443610)
17. Singleton AB, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841. (Pubitemid 37339619)
18. Polymeropoulos MH, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 1996;274 (5290):1197-9. (Pubitemid 26389286)
19. Uversky VN. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn. 2003;21:211.
20. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477(7362):107-110.
21. Jenco JM, Rawlingson A, Daniels B, Morris A. J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry. 1998;37:4901-9. (Pubitemid 28175972)
22. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443.
23. McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of α-synuclein in intact neurons. J Biol Chem. 2000;275:8812.
24. Nemani VM, et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66-79.
25. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration. Cell. 2005;123:383-96. (Pubitemid 41546670)
26. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Südhof TC. alpha-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663-7.
27. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP Administration. Neurotoxicology. 2004;25:761-9. (Pubitemid 39013325)
28. Klivenyi P, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis. 2006;21:541-8. (Pubitemid 43277537)
29. Greten-Harrison B, et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci USA. 2010;107(45):19573-8.
30. MacLeod D, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52:587-93. (Pubitemid 44781171)
31. Smith WW, et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:1231-3. (Pubitemid 44454261)
32. West AB, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA. 2005;102:16842-7. (Pubitemid 41688864)
33. Heo HY, et al. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res. 2010;316:649-56.
34. Milosevic J, et al. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol neurodegener. 2009;4:25.
35. Lin X, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron. 2009;64:807-27.
36. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308-18. (Pubitemid 34305686)
37. Ng CH, et al. Parkin protects against LRRK2 G2019S mutantinduced dopaminergic neurodegeneration in Drosophila. J Neurosci. 2009;29:11257-62.
38. Paisan-Ruiz C, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595-600. (Pubitemid 39531224)
39. Schüle B, Reijo Pera RA, Langston JW. Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta. 2009;1792:1043-51.
40. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990; 79:581-3. (Pubitemid 20170333)
41. Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-7. (Pubitemid 39531225)
42. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101-12. (Pubitemid 46432529)
43. Masliah E, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265.
44. van der Putten H, et al. Neuropathology in mice expressing human α-synuclein. J Neurosci. 2000;20:6021-9. (Pubitemid 30658395)
45. Kahle PJ, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365-73.
46. Li Y, LiuW, Oo TF,Wang L, Tang Y, Jackson-Lewis V, et al.Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci. 2009;12:826-8.
47. Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord. 2003;18 Suppl 6:S21-7. (Pubitemid 37185192)
48. Kirik D, et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA. 2003;100:2884-9. (Pubitemid 36297593)
49. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003;4:727-38. (Pubitemid 37280152)
50. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72. (Pubitemid 350138099)
51. Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
52. Paisan-Ruiz C, et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology. 2005;65: 696-700. (Pubitemid 41285847)
53. Hernandez D, et al. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci lett. 2005;389:137-9. (Pubitemid 41267214)
54. Nichols WC, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet. 2005;365:410-2. (Pubitemid 40179227)
55. Kachergus J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet. 2005;76:672-80. (Pubitemid 40432174)
56. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009;24:2175-86.
57. Ibanez P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004;364: 1169-71. (Pubitemid 39296605)
58. Waters CH, Miller CA. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol. 1994;35:59-64. (Pubitemid 24027607)
59. Park IH, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877-86.
60. Soldner F, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136:964-77.
61. Israel MA, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
62. Byers B, et al. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 2011, 6:e26159.
63. Nguyen HN, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8:267-280.
64. Dimos JT, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218-21.
65. Ebert AD, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277-80.